What are the cardiac risks, especially QT‑interval prolongation, when brexpiprazole (Rexulti) is combined with fluoxetine and trazodone?

Cardiac Safety of Brexpiprazole (Rexulti), Fluoxetine, and Trazodone Combination

Brexpiprazole carries negligible QT risk, but combining fluoxetine and trazodone creates moderate cardiac risk because both agents prolong the QT interval at therapeutic doses, and trazodone specifically inhibits hERG channels at clinically relevant concentrations. 1, 2, 3

---

Individual Drug Cardiac Profiles

Brexpiprazole (Rexulti)

• Low-quality evidence demonstrates that brexpiprazole does not increase QT interval in randomized controlled trials and systematic reviews. 2
• Among atypical antipsychotics, brexpiprazole ranks alongside aripiprazole and lurasidone as having negligible QT-prolongation risk, whereas ziprasidone, iloperidone, and amisulpride carry the highest risk. 4, 5
• Real-world pharmacovigilance data confirm that brexpiprazole is associated with the lowest reporting rates of QT prolongation among second-generation antipsychotics. 5

Fluoxetine

• Fluoxetine demonstrates a lack of clinically significant QTc increases in the majority of studies at traditional therapeutic doses. 6
• Among SSRIs, citalopram and escitalopram carry the highest QT risk, whereas paroxetine and sertraline have negligible risk; fluoxetine occupies an intermediate position with low but non-zero risk. 4, 6
• The FDA label documents that fluoxetine overdose has been associated with ECG abnormalities including QT prolongation and ventricular tachycardia, including torsades de pointes. 7
• Post-acute coronary syndrome studies showed fluoxetine did not demonstrate QTc prolongation risk, supporting its relative safety in cardiac populations at therapeutic doses. 6

Trazodone

• Trazodone inhibits hERG channel current with an IC₅₀ of 0.69 μM, which falls within clinically relevant plasma concentrations, and prolongs both QT interval and action potential duration in a reverse frequency-dependent manner. 3
• The FDA label explicitly warns: "Avoid the use of trazodone in combination with other drugs known to prolong QTc," listing Class 1A and Class 3 antiarrhythmics, antipsychotics (ziprasidone, chlorpromazine, thioridazine), and fluoroquinolone antibiotics. 1
• Retrospective poison center data identified trazodone as having a statistically significant association with QTc >500 ms in overdose cases, despite not being classified in CredibleMeds' "Known Risk of TdP" category. 8
• When trazodone is combined with strong CYP3A4 inhibitors (e.g., fluoxetine is a moderate CYP3A4 inhibitor), the risk of cardiac arrhythmias increases due to elevated trazodone exposure. 1

---

Risk Assessment for the Combination

Additive QT Prolongation

• The 2023 Canadian Cardiovascular Society guideline states that an ECG should be obtained before initiating a QT-prolonging drug if the patient is already receiving another QT-prolonging drug. 4
• The combination of fluoxetine and trazodone creates two concurrent QT-prolonging agents, which mandates baseline ECG measurement with QTc calculation. 4, 9
• QTc ≥500 ms or an increase >60–70 ms from baseline defines high risk for torsades de pointes and requires immediate drug discontinuation and continuous cardiac monitoring. 4, 9

Drug Interaction Concerns

• Fluoxetine is a potent CYP2D6 inhibitor and moderate CYP3A4 inhibitor, which can increase trazodone plasma levels and amplify its QT-prolonging effect. 1, 7
• The FDA trazodone label explicitly states: "If trazodone is used with a potent CYP3A4 inhibitor, the risk of adverse reactions, including cardiac arrhythmias, may be increased and a lower dose of trazodone should be considered." 1

Serotonin Syndrome Risk

• Both fluoxetine and trazodone are serotonergic agents; their combination increases the risk of serotonin syndrome, which presents with autonomic instability (tachycardia, labile blood pressure, hyperthermia) that can independently stress the cardiovascular system. 1, 7
• The FDA labels for both drugs warn about serotonin syndrome when combining serotonergic agents. 1, 7

---

Clinical Management Algorithm

Step 1: Baseline Cardiac Assessment (Mandatory)

• Obtain a 12-lead ECG with QTc measurement before initiating the combination. 4, 9
• Measure serum potassium (target >4.0 mmol/L, optimally 4.5–5.0 mmol/L), magnesium (>2.0 mg/dL), and calcium; correct any abnormalities before starting therapy. 4, 9
• Review all concurrent medications using crediblemeds.org to identify additional QT-prolonging agents (macrolides, fluoroquinolones, antiarrhythmics, antiemetics). 4, 9

Step 2: Risk Stratification

• High-risk patients (female sex, age >60 years, structural heart disease, baseline QTc >480 ms, concurrent diuretic use, renal impairment) require more intensive monitoring. 4, 9
• If baseline QTc is ≥500 ms or >480 ms with risk factors, do not initiate the combination; substitute fluoxetine with sertraline or paroxetine (negligible QT risk) and replace trazodone with mirtazapine or low-dose quetiapine for sedation. 4, 10

Step 3: Dose Optimization

• Start trazodone at the lowest effective dose (25–50 mg) and titrate slowly, given the pharmacokinetic interaction with fluoxetine. 1
• Fluoxetine should be maintained at standard doses (20–40 mg daily for depression); doses >40 mg increase CYP inhibition and trazodone exposure. 1, 7

Step 4: Follow-Up Monitoring

• Repeat ECG at 1 week and 2 weeks after therapy initiation, and after any dose adjustment of either drug. 10, 9
• Discontinue the regimen immediately if QTc exceeds 500 ms or rises by >60–70 ms from baseline. 4, 9
• Monitor electrolytes every 2–4 weeks during the first 3 months, especially in patients on diuretics or with renal impairment. 4, 9

Step 5: Patient Education

• Instruct patients to report palpitations, dizziness, syncope, or presyncope immediately, as these may signal ventricular arrhythmias. 11, 4
• Warn against over-the-counter medications (e.g., diphenhydramine, which is associated with QTc prolongation) and herbal supplements (e.g., St. John's Wort, which induces CYP3A4 and reduces trazodone levels). 1, 8

---

Safer Alternative Strategies

Replace Fluoxetine

• Substitute fluoxetine with sertraline (50–200 mg daily) or paroxetine (20–50 mg daily), both of which have negligible QT-prolongation potential and eliminate the primary cardiac risk. 4, 10, 6
• Sertraline has the lowest potential for warfarin drug interactions among SSRIs, making it preferable in patients on anticoagulants. 10, 12

Replace Trazodone

• Substitute trazodone with mirtazapine (7.5–30 mg at bedtime) for sedation and appetite stimulation, or low-dose quetiapine (25–100 mg at bedtime) for insomnia, both of which have lower hERG affinity than trazodone. 10, 3
• Mirtazapine does not inhibit hERG channels and carries minimal QT risk at therapeutic doses. 10

Optimize Brexpiprazole Monotherapy

• If the primary indication is depression with psychotic features or treatment-resistant depression, brexpiprazole monotherapy (1–3 mg daily) avoids polypharmacy-related QT risk and has demonstrated efficacy as an adjunct to antidepressants. 2, 5

---

Critical Pitfalls to Avoid

• Do not assume all SSRIs have equivalent cardiac safety; citalopram and escitalopram carry the highest QT risk, whereas sertraline and paroxetine are essentially negligible. 4, 6
• Do not overlook trazodone's hERG inhibition; it prolongs QT at clinically relevant concentrations and is frequently underestimated as a cardiac risk. 1, 8, 3
• Do not add multiple QT-prolonging agents without checking crediblemeds.org for drug interactions and cumulative risk. 4, 9
• Do not initiate the combination without a baseline ECG; failure to obtain pre-treatment QTc is the most critical prescribing error. 10, 9
• Do not ignore electrolyte abnormalities; hypokalemia and hypomagnesemia are the most common contributors to acquired long-QT syndrome and must be corrected before attributing QT prolongation to medications. 4, 9
• Do not use amiodarone or procainamide to treat ventricular arrhythmias in the setting of prolonged QT, as they exacerbate QT prolongation; treat torsades de pointes with IV magnesium and temporary pacing if needed. 9